Why UnitedHealth Stock Dropped 50%: The MCR Crisis Explained
UnitedHealth’s stock crash from over $600 to around $310-$320 (nearly 50% down) in the past year, isn’t just market noise. It’s a fundamental breakdown driven by one metric: the Medical Care Ratio (MCR). And here’s the kicker—even Optum, the segment that was supposed to save the day, is struggling, too.
But what exactly caused the stock to tank?
The collapse happened in two brutal phases of earnings damage and valuation multiple collapse. Before we dive into the specifics, if you seek an upside with less volatility than holding an individual stock like UNH, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell 2000, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Pixabay
Phase 1: Earnings Got Crushed
- What happened to the MCR? It exploded. The consolidated MCR jumped from a stable ~82% in 2022 to around ~88% by late 2025, with some quarters hitting 89.9%. That’s a roughly 600 basis point increase, eating directly into profits.
- Why did this matter so much? Medicare Advantage members started using way more medical services than expected. When you’re paying out that much more in claims while revenue growth can’t keep pace, profitability collapses.
- How bad was the earnings damage? Management had to slash their 2025 Adjusted EPS guidance from around $29.50-$30.00 down to at least $16.25. That’s over $13 per share of expected earnings—just gone.
Phase 2: The Valuation Multiple Collapsed
Why did investors bail? UNH used to command a premium valuation (P/E of 24x-26x) because it delivered reliable, double-digit earnings growth. The MCR shock destroyed that predictability overnight.
- P/E Multiple in 2022: ~24x-26x
- P/E Multiple in 2025: ~16x-17x
- The drop: Down 8-10 points
- Stock price impact: What was (High Multiple × High EPS) became (Low Multiple × Low EPS)—a double hit
Investors aren’t willing to pay a premium for earnings that now look uncertain and volatile. The market now treats UNH like a lower-quality, higher-risk business.
Wait, wasn’t Optum supposed to offset this?
That’s what everyone thought. For years, Optum’s high-growth story insulated UNH from insurance market swings. Not anymore.
What’s going wrong with Optum?
- Medicare funding cuts are hitting this business too
- The value-based care model (Optum Health) is facing the same utilization headwinds
- Heavy investment costs are eating into margins
How bad is it? Optum’s operating earnings are projected to decline year-over-year in 2025—from ~$16.7 billion in 2024 to around $12.5-$12.8 billion.
Why is this such a problem? UNH just lost both its growth engine and its profit buffer at the same time. There’s no safety net left.
So what happens next?
Is the stock cheap now at 16x-17x earnings? On the surface, yes—it’s trading well below its historical 25x average. But that discount is justified right now. Until the MCR stabilizes and Optum rebounds, UNH looks more like a low-margin, cyclical insurance company than the premium healthcare tech leader it used to be.
What needs to happen for a recovery?
Three things:
- MCR stabilization – Clear proof that medical utilization is normalizing
- 2026 premium pricing – Successfully raising premiums enough to recover lost margins (bids are filed months in advance, so investors are watching closely)
- Optum re-acceleration – The growth segment needs to get back on track
What’s the biggest risk? If management miscalculates 2026 pricing or if the MCR remains persistently elevated, the stock’s current low multiple could be sustained indefinitely, limiting upside.
To counter this single-stock vulnerability, investors should explore diversified strategies like the Trefis Reinforced Value (RV) Portfolio. This portfolio has consistently outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 indices), delivering strong returns.
Why the outperformance? The RV Portfolio’s success, as detailed in its performance metrics, lies in its quarterly rebalanced mix of large-, mid-, and small-cap stocks. This responsive strategy is designed to effectively capitalize on favorable market conditions while simultaneously limiting losses when markets head south.
Bottom Line
The MCR spike delivered a one-two punch: it slashed earnings AND killed the valuation multiple. A real recovery won’t come from stabilization alone—it requires a credible path back to double-digit growth, which means fixing the MCR problem in UnitedHealthcare and reigniting growth in Optum. Until both happen, expect continued pressure.
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates